Driehaus Capital Management LLC Grows Stake in Integer Holdings Co. (NYSE:ITGR)

Driehaus Capital Management LLC increased its holdings in shares of Integer Holdings Co. (NYSE:ITGR) by 62.5% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 353,052 shares of the medical equipment provider’s stock after acquiring an additional 135,750 shares during the period. Driehaus Capital Management LLC’s holdings in Integer were worth $40,880,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Quest Partners LLC boosted its stake in Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 332 shares during the last quarter. GAMMA Investing LLC boosted its stake in Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 142 shares during the last quarter. Headlands Technologies LLC bought a new position in Integer during the first quarter valued at approximately $106,000. Innealta Capital LLC bought a new position in Integer during the second quarter valued at approximately $110,000. Finally, Hancock Whitney Corp bought a new position in Integer during the first quarter valued at approximately $203,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Analyst Upgrades and Downgrades

ITGR has been the subject of a number of research reports. Oppenheimer started coverage on Integer in a research note on Tuesday, July 16th. They set an “outperform” rating and a $135.00 price target for the company. Benchmark reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Integer in a research note on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $133.86.

Insider Transactions at Integer

In other Integer news, Director Jean M. Hobby sold 11,960 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the transaction, the director now directly owns 2,280 shares in the company, valued at approximately $272,824.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.00% of the company’s stock.

Integer Trading Down 0.9 %

Shares of NYSE ITGR opened at $125.90 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.96 and a current ratio of 3.29. The business’s 50 day moving average price is $123.34 and its 200-day moving average price is $119.04. Integer Holdings Co. has a fifty-two week low of $69.40 and a fifty-two week high of $131.87. The company has a market cap of $4.22 billion, a price-to-earnings ratio of 43.56, a PEG ratio of 1.87 and a beta of 1.09.

Integer (NYSE:ITGR) last issued its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.06. Integer had a return on equity of 11.48% and a net margin of 6.31%. The firm had revenue of $436.20 million for the quarter, compared to the consensus estimate of $437.00 million. During the same period in the prior year, the business posted $1.14 earnings per share. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. On average, sell-side analysts expect that Integer Holdings Co. will post 5.31 earnings per share for the current year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.